Akebia Therapeutics Inc

Despite the long-term downtrend, AKBA’s early Stage 1 base and the Bullish Pivot Point suggest upward mean-reversion potential. Price is currently extended above the rising short EMAs and testing resistance at the 50-day SMA without clear exhaustion, so execution should be deferred. We will await a pullback into the 9/21 EMA support zone near the base lows before initiating participation.

• ↑Vafsio net revenues reached $15.8M in Q1, up 32% YoY.
• ↑VOICE trial interim data shows improved safety for anemia management.
• ↓Q1 total revenues dropped to $53.5M from $57.3M YoY.